MCG Pharma

Executive Summary

MCG Pharma is a European commercial-stage pharmaceutical company headquartered in Zagreb, Croatia, founded in 2006. The company is dedicated to making treatments accessible across a broad range of therapeutic areas, including Oncology, Infectious Disease, Pediatrics, Hematology, Gastroenterology, and Rare Diseases. By leveraging a partnership and distribution-focused business model, MCG Pharma serves markets in Turkey and internationally, positioning itself as a key player in providing essential medicines to underserved regions. With a strong emphasis on collaborations, MCG Pharma has built a diversified portfolio that addresses both high-need and niche therapeutic areas. The company's strategy involves in-licensing and distributing products from global partners, which allows it to expand its reach without heavy R&D costs. Looking ahead, MCG Pharma is well-positioned to benefit from increasing demand for affordable treatments in emerging markets and could pursue further expansion into the EU and other regions. However, limited public visibility on its pipeline and financial performance constrains conviction in near-term catalysts.

Upcoming Catalysts (preview)

• TBDNew market expansion into the EU or other regions50% success
• TBDProduct launch or in-licensing deal in oncology or infectious disease40% success
• TBDStrategic partnership or acquisition to broaden portfolio30% success